Evidence map›Paper›PMID 26946161›Full record

ArticleThe Journal of urology2016

How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States.

Stacy Loeb, Dawn Walter, Caitlin Curnyn, Heather T Gold, Herbert Lepor, Danil V Makarov

Abstract readMulticenter Study
In one paragraph

Article in The Journal of urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Active Surveillance for Localized Prostate Cancer: A Retrospective Single-Center Study.International journal of urology : official journal of the Japanese Urological Association · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Stacy LoebDepartment of Urology, New York University, New York, New York; Population Health, New York University, New York, New York; Laura and Isaac Perlmutter Cancer Center, New York University, New York, New York. Electronic address: stacyloeb@gmail.com.
Dawn WalterPopulation Health, New York University, New York, New York.
Caitlin CurnynPopulation Health, New York University, New York, New York.
Heather T GoldPopulation Health, New York University, New York, New York.
Herbert LeporDepartment of Urology, New York University, New York, New York.
Danil V MakarovDepartment of Urology, New York University, New York, New York; Population Health, New York University, New York, New York; Laura and Isaac Perlmutter Cancer Center, New York University, New York, New York.

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Richard Lewis Possemato · 1985 to 2026
$83.1M
Optimal Strategy for Conservative Management of Prostate CancerK07CA178258 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LOEB, STACY · 2013 to 2017
$889k
Optimizing Imaging Use Among Veterans with Prostate CancerIK2HX000851 · VA · VA MEDICAL CENTER · PI MAKAROV, DANIL V. · 2014 to 2015
–
HSRD VA IK2 HX000851NCI NIH HHS K07 CA178258NCI NIH HHS P30 CA016087
6 · The paper itself

Abstract

purposeWhile major prostate cancer active surveillance programs recommend repeat testing such as prostate specific antigen and prostate biopsy, to our knowledge compliance with such testing is unknown. We determined whether men in the community receive the same intensity of active surveillance testing as in prospective active surveillance protocols. MATERIALS AND

methodsWe performed a retrospective cohort study of men 66 years old or older in the SEER (Surveillance, Epidemiology and End Results)-Medicare database. These men were diagnosed with prostate cancer from 2001 to 2009, did not receive curative therapy in the year after diagnosis and underwent 1 or more post-diagnosis prostate biopsies. We used multivariable adjusted Poisson regression to determine the association of the frequency of active surveillance testing with patient demographics and clinical features. In 1,349 men with 5 years of followup we determined the proportion who underwent testing as intense as that recommended by the Sunnybrook Health Sciences Centre and PRIAS (Prostate Cancer Research International Active Surveillance) programs, including 14 or more PSA tests and 2 or more biopsies, and The Johns Hopkins program, including 10 or more prostate specific antigen tests and 4 or more biopsies.

resultsAmong 5,192 patients undergoing active surveillance greater than 80% had 1 or more prostate specific antigen tests per year but fewer than 13% underwent biopsy beyond the first 2 years. Magnetic resonance imaging was rarely done during the study period. On multivariable analysis recent diagnosis and higher income were associated with a higher frequency of surveillance biopsy while older age and greater comorbidity were associated with fewer biopsies. African American men underwent fewer prostate specific antigen tests but a similar number of biopsies. During 5 years of active surveillance only 11.1% and 5.0% of patients met the testing standards of the Sunnybrook/PRIAS and The Johns Hopkins programs, respectively.

conclusionsIn the community few elderly men receive the intensity of active surveillance testing recommended in major prospective active surveillance programs.

Indexed as

Patient ComplianceSEER ProgramAgedAged, 80 and overBiopsyFollow-Up StudiesHumansMagnetic Resonance ImagingMaleMorbidityProstateProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesTime FactorsUnited StatesProstate-Specific Antigenagedprostatic neoplasmsSEER programstandard of carewatchful waiting

Identifiers

PMID26946161
PMCPMC5010531

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.